On that subject, for VHA contracts, SNY dropped the price of Lovenox by 40% in July. I believe this is way more aggressive than Sandoz expected and is probably behind the continual drop in the stock, as I believe the legal issues pose minimal risk.
As I have said, I agree that revenue uncertainty is the number one reason for the price drop. The market needs to see actual sales numbers. I am optimistic that the numbers will be good, but I could easily be wrong. I have asked a couple sources for script numbers, but have not gotten anything yet (other than first week numbers that showed almost 0 sales).
I was expecting a decision before market open today, so I am very disappointed in market price right now.
Market Data 
Markets 
AI
